PRRG3 Inhibitors
Chemical inhibitors of PRRG3 employ a variety of mechanisms to inhibit the activity of this protein. Staurosporine serves as a potent kinase inhibitor, preventing the phosphorylation necessary for PRRG3 activation. Similarly, Wortmannin and LY294002 specifically target phosphoinositide 3-kinases (PI3K), disrupting the PI3K-dependent signaling pathways integral to PRRG3 function. Rapamycin follows another route by inhibiting the mTOR pathway, which is involved in the regulation of protein synthesis and cellular processes, thus indirectly suppressing PRRG3 activity. Palbociclib contributes to the inhibition by targeting cyclin-dependent kinases 4 and 6 (CDK4/6), which are crucial for cell cycle progression, a process where PRRG3 may play a role.
Further inhibition of PRRG3 is achieved through the interruption of the MAPK/ERK pathway by PD98059 and U0126, both of which are MEK inhibitors, thus preventing any MAPK/ERK pathway-mediated activation of PRRG3. In addition, SP600125, a JNK inhibitor, disrupts the stress-activated protein kinase pathways that could involve PRRG3, leading to its inhibition. SB203580 takes a similar approach by inhibiting p38 MAP kinase, thereby blocking the p38 MAPK pathways that regulate PRRG3. Dasatinib and Sunitinib, both tyrosine kinase inhibitors, inhibit PRRG3 by blocking the tyrosine kinase-dependent signaling pathways it relies on. Lastly, Triciribine acts by inhibiting Akt, which is known to regulate survival and growth signals that are critical for PRRG3 function, resulting in the downregulation of its activity. Each of these chemicals targets specific biochemical pathways or cellular processes to exert functional inhibition on PRRG3.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent inhibitor of protein kinases. It can inhibit PRRG3 by preventing the phosphorylation of the protein, which is necessary for its activation and function. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a specific inhibitor of phosphoinositide 3-kinases (PI3K). By inhibiting PI3K, it can disrupt signaling pathways that are crucial for the activity of PRRG3. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is another inhibitor of PI3K. It can inhibit PRRG3 by blocking the PI3K-dependent signaling pathways that are essential for PRRG3's function. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits the mTOR pathway. Since mTOR signaling is involved in the regulation of protein synthesis and other cellular processes, inhibiting this pathway can suppress the functional activity of PRRG3. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
Palbociclib inhibits cyclin-dependent kinases 4 and 6 (CDK4/6). By inhibiting these kinases, it can prevent cell cycle progression and other processes that PRRG3 may be involved in. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is an inhibitor of MEK, which is part of the MAPK/ERK pathway. By inhibiting MEK, PD98059 can prevent the activation of PRRG3 that may be regulated by this pathway. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is another MEK inhibitor that can block the MAPK/ERK pathway. This inhibition can suppress the functional activity of PRRG3 that relies on this pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor. By inhibiting JNK, it can disrupt stress-activated protein kinase signaling pathways that PRRG3 may be part of, leading to inhibition of PRRG3's function. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAP kinase inhibitor. It can inhibit PRRG3 by blocking the p38 MAPK signaling pathways that are involved in regulating PRRG3. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a broad-spectrum tyrosine kinase inhibitor. It can inhibit PRRG3 by blocking tyrosine kinase-dependent signaling pathways that PRRG3 is involved in. | ||||||